Study on the preventive mechanism of Buyang Huanwu Decoction in Alzheimer′s disease based on network pharmacology
WANG Baiyun1 LIU Guoliang2 PIAO Chengyu3 CHEN Qiaoyun2 CHEN Jinghua2 XUE Hui2 LIU Bin2
1.Department of Pharmacy, Jinzhou Central Hospital, Liaoning Province, Jinzhou 121000, China;
2.Jiamusi College of Heilongjiang University of Chinese Medicine, Heilongjiang Province, Jiamusi 154007, China;
3.Center for Drug Safety Evaluation, Heilongjiang University of Traditional Chinese Medicine, Heilongjiang Province, Harbin 150040, China
Abstract：Objective To predict and discover the target of Buyang Huanwu Decoction in the prevention and treatment of Alzheimer′s disease (AD) and explore the synergistic mechanism of multi-component, multi-target and multi-pathway. Methods According to the composition of Buyang Huanwu Decoction, the in vivo target of Buyang Huanwu Decoction was predicted by multiple network pharmacology methods. The target of anti-AD drug was selected by BATMAN-TCM and other databases. Finally, the components of Buyang Huanwu Decoction were constructed by Cycaptose software for target path network. Results The active components of Buyang Huanwu Decoction were involved in many targets directly related to Alzheimer′s disease, such as apolipoprotein E (APOE). At the same time, it involves many metabolic pathways, such as glycerol phospholipid metabolism, cholinergic synapses, cholesterol metabolism, Alzheimer′s disease pathway and so on. Conclusion Buyang Huanwu Decoction mainly works through multi-component synergy, such as 1-hexadecence regulates apoliporotein E indirectly to regulate the formation of hydrophobic amyloid β (Aβ), the inhibition of safranal on acetylcholinesterase and butyrocholinesterase, thus delaying the occurrence and development of AD.
汪白云1 刘国良2 朴成玉3 陈巧云2 陈景华2 薛慧2 刘斌2. 基于网络药理学的补阳还五汤防治阿尔茨海默病的机制研究[J]. 中国医药导报, 2019, 16(6): 12-15.
WANG Baiyun1 LIU Guoliang2 PIAO Chengyu3 CHEN Qiaoyun2 CHEN Jinghua2 XUE Hui2 LIU Bin2. Study on the preventive mechanism of Buyang Huanwu Decoction in Alzheimer′s disease based on network pharmacology. 中国医药导报, 2019, 16(6): 12-15.
[1] Selkoe DJ. Alzheimer′s disease：genes，proteins，and therapy [J]. Physiol Rev，2001，81（2）：741-766.
[2] McKhann G，Drachman D，Folstein M，et al. Clinical diagnosis of Alzheimer′s disease：report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer′s Disease [J]. Neurology，1984，34（7）：939-944.
[3] Klunk WE，Engler H，Nordberg A，et al. Imaging brain amyloid in Alzheimer′s disease with Pittsburgh Compound-B [J]. Ann Neurol，2010，55（3）：306-319.
[4] Harold D，Abraham R，Hollingworth P，et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer′s disease [J]. Nature Genetics，2009，41（10）：1094-1099.
[5] Sperling RA，Al E. Toward defining the preclinical stages of Alzheimer′s disease：recommendations from the National Institute on Aging-Alzheimer′s Association workgroups on diagnostic guidelines for Alzheimer′s disease [J]. Alzheimers Dement，2011，7（3）：280-292.
[6] Terry RD，Masliah E，Salmon DP，et al. Physical basis of cognitive alterations in Alzheimer′s disease：synapse loss is the major correlate of cognitive impairment [J]. Ann Neurol，2010，30（4）：572-580.
[7] 龙旭阳，方衡，王发善，等.补阳还五汤挥发性成分指纹图谱的研究[J].中医药现代化，2014（3）：560-564.
[8] 刘斌，熊辉，朴成玉，等.补阳还五汤的HPLC指纹图谱研究[J].中医药学报，2016，44（4）：5-9.
[9] 叶肖栗，叶伟峰，张继业，等.HPLC法测定补阳还五汤中主要成分及其代谢研究[J].药物分析杂志，2016（5）：765-775.
[10] Shaw LH，Chen WM，Tsai TH. Identification of multiple ingredients for a Traditional Chinese Medicine preparation （bu-yang-huan-wu-tang）by liquid chromatography coupled with tandem mass spectrometry [J]. Molecules，2013，18（9）：11281-11298.
[11] 廖卫国.UPLC-MS/LSCI法补阳还五汤大鼠药动学研究及药效探索[D].广州：广州中医药大学，2016.
[12] 赵金尧.补阳还五汤中多糖、黄酮、挥发油的提取和分析[D].长沙：中南大学，2005.
[13] 黄海艳，祝赫，韩彬，等.补阳还五汤血浆指纹图谱的建立[J].中国实验方剂学杂志，2016（15）：96-99.
[14] Lee-Hsin S，Lin LC，Tung-Hu T. HPLC–MS/MS Analysis of a Traditional Chinese Medical Formulation of Bu-Yang-Huan-Wu-Tang and Its Pharmacokinetics after Oral Administration to Rats [J]. PLoS One，2012，7（8）：e43848.
[15] 熊杰，白生华，徐万清，等.阿尔茨海默病患者血清C反应蛋白、载脂蛋白E和同型半胱氨酸检测的临床意义分析[J].中国卫生检验杂志，2011，21（8）：1987-1989.
[16] 刘倩，吴为辉，李人望，等.载脂蛋白E与阿尔茨海默病的相关研究进展[J].化学进展，2007（12）：2006-2011.
[17] 牛俊茹，陈彩珍，徐波.运动、APOE4调控下的散发型阿尔茨海默病相关机制研究[J].体育科技文献通报，2016， 24（1）：3-4.
[18] 冯雪岩.ApoE等位基因与阿尔茨海默病（AD）.中华医学会、中华医学会神经病学分会.中华医学会第十七次全国神经病学学术会议论文汇编（上）[C]//中华医学会、中华医学会神经病学分会：2014.
[19] Breitner JC，Wyse BW，Anthony JC，et al. APOE-epsilon4 count predicts age when prevalence of AD increases，then declines：the Cache County Study [J]. Neurology，1999，53（2）：321.
[20] Morris JCJ，Roe CMC，Xiong CC，et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging [J]. Ann Neurol，2010，67（1）：122.
2019, Vol. 16 
京公网安备 11010502046598号